New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:49 EDTADXSAdvaxis to conduct 4 cancer immunotherapy clinical trials with GRU Cancer Center
Advaxis announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The four clinical trials will be designed to assess: High dose, repeating cycles of ADXS-HPV in recurrent or refractory cervical cancer. ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. The optimal combination dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer. ADXS-HPV prior to surgery in patients with surgically treatable cervical cancer.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
07:33 EDTADXSAdvaxis announces first patient treated in Phase 1/2 study of ADXS-HPV
Subscribe for More Information
07:14 EDTADXSWall Street Analyst Forum to hold a conference
25th Annual Investor Conference is being held in New York on March 19.
March 16, 2015
07:36 EDTADXSAdvaxis Phase 1/2 trial preliminary data shows ADXS-HPV well tolerated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use